Pediatrics
MannKind Corporation's Afrezza Receives FDA Approval sBLA for Pediatric Patients
The U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) from MannKind Corporation for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target